Literature DB >> 15278495

Modification of hepatic protein kinase C with phorbol myristate acetate and staurosporine alters hemodynamics in the perfused rat liver.

H Inaba1, M Araki, T Numai, T Mizuguchi.   

Abstract

Activation of protein kinase C (PKC) has been implicated in the pathogenesis of endotoxicosis and severe sepsis. Since hepatic blood flow and metabolism have been known to be altered in endotoxicosis and sepsis, we studied the hemodynamic effect of PKC modulation with phorbol 12-myristate 13-acetate (PMA) and staurosporine (St) on the perfused rat liver. The liver was isolated from overnight-fasted male Sprague-Dawley rats and placed in a recirculating perfusion apparatus. The liver was perfused with Krebs-Ringer-bicarbonate solution at a constant pressure of 12 cmH2O. Flow to the liver was continuously monitored with an electric magnetic flowmeter. PMA at an initial concentration of 2 x 10(-8) M significantly decreased hepatic flow. Staurosporine (St), a potent PKC inhibitor at 4 x 10(-7) M produced a small increase in hepatic flow. Pretreatment with St significantly attenuated the flow reduction by PMA. St significantly suppressed the flow reductions by 4 x 10(-6) M of prostaglandin E2 and D2. These results suggest that the PKC inside the liver may play an important role in the regulation of hepatic blood flow during endotoxicosis and sepsis.

Entities:  

Year:  1993        PMID: 15278495     DOI: 10.1007/s0054030070048

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  25 in total

Review 1.  The molecular heterogeneity of protein kinase C and its implications for cellular regulation.

Authors:  Y Nishizuka
Journal:  Nature       Date:  1988-08-25       Impact factor: 49.962

Review 2.  Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases.

Authors:  U T Rüegg; G M Burgess
Journal:  Trends Pharmacol Sci       Date:  1989-06       Impact factor: 14.819

3.  The microcirculatory hepatic unit.

Authors:  A M Rappaport
Journal:  Microvasc Res       Date:  1973-09       Impact factor: 3.514

4.  Augmentation of endotoxic lethality and glucose dyshomeostasis by phorbol ester.

Authors:  H Inaba; J P Filkins
Journal:  Am J Physiol       Date:  1991-03

Review 5.  Studies and perspectives of protein kinase C.

Authors:  Y Nishizuka
Journal:  Science       Date:  1986-07-18       Impact factor: 47.728

6.  Phorbol myristate acetate: in vivo effects upon neutrophils, platelets, and lung.

Authors:  J T O'Flaherty; S Cousart; A S Lineberger; E Bond; D A Bass; L R DeChatelet; E S Leake; C E McCall
Journal:  Am J Pathol       Date:  1980-10       Impact factor: 4.307

7.  Stimulation of hepatic glycogenolysis by phorbol 12-myristate 13-acetate.

Authors:  T B Patel
Journal:  Biochem J       Date:  1987-01-15       Impact factor: 3.857

8.  Effects of a protein kinase C inhibitor, K-252a, on human polymorphonuclear neutrophil responsiveness.

Authors:  R J Smith; J M Justen; L M Sam
Journal:  Biochem Biophys Res Commun       Date:  1988-05-16       Impact factor: 3.575

9.  Inhibitory action of chlorpromazine, dibucaine, and other phospholipid-interacting drugs on calcium-activated, phospholipid-dependent protein kinase.

Authors:  T Mori; Y Takai; R Minakuchi; B Yu; Y Nishizuka
Journal:  J Biol Chem       Date:  1980-09-25       Impact factor: 5.157

10.  Effect of RNA and protein synthesis inhibitors on the release of inflammatory mediators by macrophages responding to phorbol myristate acetate.

Authors:  R J Bonney; P D Wightman; M E Dahlgren; P Davies; F A Kuehl; J L Humes
Journal:  Biochim Biophys Acta       Date:  1980-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.